NASDAQ:CODX Co-Diagnostics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $5.84 +0.23 (+4.10%) (As of 07/1/2022 03:59 PM ET) Add Compare Share Today's Range$5.48▼$5.9350-Day Range$3.76▼$5.8452-Week Range$3.66▼$11.82Volume38,378 shsAverage Volume439,458 shsMarket Capitalization$198.49 millionP/E Ratio4.49Dividend YieldN/APrice Target$13.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Co-Diagnostics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside122.6% Upside$13.00 Price TargetShort InterestBearish5.44% of Shares Sold ShortDividend StrengthN/ASustainability-1.10Upright™ Environmental ScoreNews Sentiment0.60Based on 7 Articles This WeekInsider TradingN/AProj. Earnings Growth5.97%From $0.67 to $0.71 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.16 out of 5 starsMedical Sector315th out of 1,427 stocksSurgical & Medical Instruments Industry38th out of 138 stocks 3.4 Analyst's Opinion Consensus RatingCo-Diagnostics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Co-Diagnostics has a forecasted upside of 122.6% from its current price of $5.84.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.44% of the outstanding shares of Co-Diagnostics have been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 5.1.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCo-Diagnostics has received a 67.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Infectious disease diagnostics systems", and "PCR machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Co-Diagnostics is -1.10. Previous Next 2.0 News and Social Media Coverage News SentimentCo-Diagnostics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Co-Diagnostics this week, compared to 8 articles on an average week.Search Interest7 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 21.00% of the stock of Co-Diagnostics is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Co-Diagnostics are expected to grow by 5.97% in the coming year, from $0.67 to $0.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is 4.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 74.75.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is 4.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.15.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address About Co-Diagnostics (NASDAQ:CODX) StockCo-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Read More CODX Stock News HeadlinesJuly 4, 2022 | morningstar.co.ukOmega Diagnostics shares jump on sale of CD4 manufacturing business - MorningstarJuly 4, 2022 | finance.yahoo.comA $1.7 Billion Global Opportunity for Hemoglobin A1C (HbA1C) Testing by 2026 - New Research from StrategyR - Yahoo FinanceJuly 1, 2022 | nasdaq.comEx-Dividend Reminder: John Wiley & Sons, Quest Diagnostics and Erie Indemnity - NasdaqJune 28, 2022 | proactiveinvestors.comNA Proactive news snapshot: VR Resources, SPYR Technologies, American Manganese, BioPorto, Falcon Gold, TomaGold UPDATE ... - Proactive Investors USAJune 28, 2022 | proactiveinvestors.comNA Proactive news snapshot: enCore Energy, Nextech AR Solutions, Victory Resources, Think Research, Prospector Metals ... - Proactive Investors USAJune 28, 2022 | finance.yahoo.comCo-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual ConferenceJune 24, 2022 | nasdaq.comCoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains? - NasdaqJune 24, 2022 | finance.yahoo.comCoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?June 23, 2022 | seekingalpha.comCODX stock higher ahead of WHO emergency meeting on monkeypox (NASDAQ:CODX) - Seeking AlphaJune 22, 2022 | finance.yahoo.comGLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030 - Yahoo FinanceJune 21, 2022 | seekingalpha.comCo-Diagnostics: Well Priced, Long-Term Value Still Distant (NASDAQ:CODX) - Seeking AlphaJune 21, 2022 | globenewswire.comLumos Diagnostics Appoints Doug Ward as CEO - GlobeNewswireJune 21, 2022 | finance.yahoo.comInfectious Disease Diagnostics Market by Product, Test Type, Disease, Technology, End User - Global Forecast to 2027 - Yahoo FinanceJune 17, 2022 | finance.yahoo.comGlobal High Potency Active Pharmaceutical Ingredient (HPAPI) Market Report 2022 with Competitive Landscape Analysis of Eli Lily and Co; Novartis; Bristol-Myers Squibb; Roche Diagnostics; Sanofi - Yahoo FinanceJune 17, 2022 | bloomberg.comCharles Strom on the Diagnostics Industry - BloombergJune 16, 2022 | businesswire.comGlobal Rapid Diagnostics Market Forecast Report 2022-2029 with Market Share Analysis of Leading Players - Abbott Laboratories, Becton, Dickinson and Co, & F. Hoffmann-La Roche - ResearchAndMarkets.com - Business WireJune 15, 2022 | proactiveinvestors.comNA Proactive news snapshot: Valeo Pharma, Looking Glass Labs, AMPD Inc, Trees Corp, Tocvan Ventures ... - Proactive Investors USAJune 15, 2022 | benzinga.comCo-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference - Benzinga - BenzingaJune 15, 2022 | finance.yahoo.comGlobal Molecular Diagnostics Markets Report 2022: A $30+ Billion Market by 2027 - Rising Focus on R&D and Growing Funding and Growth Opportunities in Emerging Countries - Yahoo FinanceJune 15, 2022 | finance.yahoo.comCo-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual ConferenceJune 14, 2022 | globenewswire.comGlobal in vitro diagnostic devices market size to grow at 6.7% CAGR through 2028 - GlobeNewswireJune 14, 2022 | finance.yahoo.comWorld Molecular Diagnostics Markets, 2022-2027 - Increasing Prevalence of Infectious Diseases and Cancer is Expected to Support Market Growth - Yahoo FinanceJune 11, 2022 | benzinga.comCo-Diagnostics, Inc. to Host Booth at MEDEXPO Africa 2022 in Nairobi, Kenya on June 9-11 - BenzingaJune 9, 2022 | finance.yahoo.comCo-Diagnostics, Inc. to Host Booth at MEDEXPO Africa 2022 in Nairobi, Kenya on June 9-11June 8, 2022 | finance.yahoo.comGlobal Cancer Pain Diagnostics Market is Projected to Reach US$ 9,951.2 Million by 2030 – Exclusive Study by Astute Analytica - Yahoo FinanceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CODX CUSIPN/A CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees101Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/04/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+122.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.30 Trailing P/E Ratio4.49 Forward P/E Ratio8.72 P/E GrowthN/ANet Income$36.66 million Net Margins40.25% Pretax Margin48.58% Return on Equity32.20% Return on Assets28.57% Debt Debt-to-Equity RatioN/A Current Ratio9.63 Quick Ratio9.25 Sales & Book Value Annual Sales$97.89 million Price / Sales2.03 Cash Flow$1.28 per share Price / Cash Flow4.56 Book Value$4.65 per share Price / Book1.26Miscellaneous Outstanding Shares33,988,000Free Float33,648,000Market Cap$198.49 million OptionableNot Optionable Beta-1.71 Co-Diagnostics Frequently Asked Questions Should I buy or sell Co-Diagnostics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Co-Diagnostics stock. View analyst ratings for Co-Diagnostics or view top-rated stocks. What is Co-Diagnostics' stock price forecast for 2022? 4 equities research analysts have issued 1 year price targets for Co-Diagnostics' shares. Their CODX stock forecasts range from $12.00 to $14.00. On average, they anticipate Co-Diagnostics' stock price to reach $13.00 in the next year. This suggests a possible upside of 122.6% from the stock's current price. View analysts' price targets for Co-Diagnostics or view top-rated stocks among Wall Street analysts. How has Co-Diagnostics' stock performed in 2022? Co-Diagnostics' stock was trading at $8.93 on January 1st, 2022. Since then, CODX shares have decreased by 34.6% and is now trading at $5.84. View the best growth stocks for 2022 here. When is Co-Diagnostics' next earnings date? Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Co-Diagnostics. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) issued its earnings results on Thursday, May, 12th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.18 by $0.08. The firm earned $22.70 million during the quarter, compared to analysts' expectations of $21.25 million. Co-Diagnostics had a net margin of 40.25% and a trailing twelve-month return on equity of 32.20%. During the same quarter in the previous year, the business earned $0.26 earnings per share. View Co-Diagnostics' earnings history. What guidance has Co-Diagnostics issued on next quarter's earnings? Co-Diagnostics updated its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided EPS guidance of $0.170-$0.200 for the period, compared to the consensus estimate of $0.110. The company issued revenue guidance of $21 million-$22 million, compared to the consensus revenue estimate of $21.28 million. Who are Co-Diagnostics' key executives? Co-Diagnostics' management team includes the following people: Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 69, Pay $1.02M)Mr. Brian L. Brown CPA, CFO & Company Sec. (Age 46, Pay $730.62k)Mr. Reed L. Benson, Gen. Counsel (Age 74, Pay $385.85k) (LinkedIn Profile)Dr. Brent C. Satterfield Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 45)Dr. Jesse Montgomery, Chief Scientific OfficerMr. Andrew Benson, Head of Investor RelationsDr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic AlliancesMr. Cameron Gundry, Head of Commercialization LATAM/EUR Who are some of Co-Diagnostics' key competitors? Some companies that are related to Co-Diagnostics include Artivion (AORT), AngioDynamics (ANGO), Alphatec (ATEC), UFP Technologies (UFPT), Cardiovascular Systems (CSII), TransEnterix (TRXC), Pulmonx (LUNG), Bioventus (BVS), Surmodics (SRDX), Alpha Tau Medical (DRTS), Orthofix Medical (OFIX), Sight Sciences (SGHT), SI-BONE (SIBN), Inovio Pharmaceuticals (INO) and IRadimed (IRMD). View all of CODX's competitors. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ). When did Co-Diagnostics IPO? (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. What is Co-Diagnostics' stock symbol? Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX." How do I buy shares of Co-Diagnostics? Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Co-Diagnostics' stock price today? One share of CODX stock can currently be purchased for approximately $5.84. How much money does Co-Diagnostics make? Co-Diagnostics (NASDAQ:CODX) has a market capitalization of $198.49 million and generates $97.89 million in revenue each year. The company earns $36.66 million in net income (profit) each year or $1.30 on an earnings per share basis. How many employees does Co-Diagnostics have? Co-Diagnostics employs 101 workers across the globe. How can I contact Co-Diagnostics? Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The official website for Co-Diagnostics is www.codiagnostics.com. The company can be reached via phone at (801) 438-1036 or via email at investors@codiagnostics.com. This page (NASDAQ:CODX) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
